Lumenis Be. Ltd. has launched a new addition to its ophthalmic medical device product line: OptiLIFT, a proprietary-based dynamic muscle stimulation technology (DMSt) designed to tone facial muscles to treat lower lid laxity and impaired blinking.
The device is now available on the U.S. market.
How exciting! But first, a rundown on Lumenis.
With U.S. headquarters in Santa Clara, California, the global energy-based medical device company specializes in minimally-invasive clinical solutions for three markets:
And its products?
Among its wide range of technology offerings, the company’s dry eye-focused solutions include:
- OptiLIGHT
- What it is: The first and only intense pulsed light (IPL) therapy FDA-approved for the management of dry eye disease (DED) due to meibomian gland dysfunction (MGD)
- OptiPLUS
- What it is: The first dual frequency radiofrequency (RF) device in the U.S. designed to deliver heat across tissue layers, leading to a potential increase in blood circulation with the goal of improving medical performance and aesthetic results.
Now talk about this newest technology.
We’ll start with the tech it utilizes: Dynamic muscle stimulation technology (DMSt).
- What it is: A noninvasive treatment involving electrical impulses that trigger nerve signals to activate facial muscles, tightening and toning the underlying facial structure.
Some background: Already utilized in Lumenis’s triLift for aesthetic purposes (toning the cheek, jowl line, and under-eyes areas), the resulting effect of DMSt is a more natural, lifted look—all without surgery or injections.
And for OptiLIFT?
OptiLIFT’s DMSt is specifically designed to tighten and tone the muscles of the periorbital area.
Important to note: The procedure must be performed by a trained clinician in an office setting (for both dermatological and general surgical procedures).
Real quick: Why focus on the periorbital region?
First thing to know: Muscle mass decreases an estimated 3 to 8% per decade after the age of 30—with that rate of decline even higher after the age of 60.
As such: Muscles in the periorbital area begin to weaken during this natural aging process, leading to reduced structural support and resulting in two key effects:
- Lower lid laxity
- Incomplete blinking
In the context of dry eye: Lower lid laxity is known to play a significant role in creating ocular surface problems, with more than 60% of symptomatic dry eye patients presenting with impaired lid closure.
As for incomplete blinking: This has been referred to as an often overlooked and under-diagnosed condition indicative of dry eye.
Got it. Now back to this device.
According to Lumenis, OptiLIFT uses an RF component that delivers heat to skin layers to enhance collagen formation around the periorbital region.
- The intended outcome: Addressing the lower lids’ gravitational descent and enhancing blink dynamics.
Notably: The device is also available with an optional RF microneedling upgrade (the VoluDerm microneedling applicator), which involves “ultra-thin needles and a double RF mechanism to increase skin smoothness by 80% and triple hyaluronic acid (HA) production.”
Circling back to HA … why is production of this important?
In general: HA is a naturally occurring substance present in the skin that helps retain moisture and provide skin elasticity (generating a more youthful, wrinkle-free appearance).
Looking specifically at the periorbital area: HA production naturally decreases as a person ages.
- The result: This can lead to noticeable aging signs on the skin, including wrinkles and hollowing under the eyes.
Bringing this back to OptiLIFT: An increase in HA production helps the skin to tighten, retain moisture, and present as wrinkle-free.
I have to ask: Is there any clinical data on the device yet?
There is! However, those results are not yet available to the public.
Here’s what we do know:
A clinical study on OptiLIFT and DMSt was performed by James Chelnis, MD, FACS, an ophthalmic plastic and reconstructive surgeon at Manhattan Face & Eye.
While no details were released as to the specifics of the study, the company shared: “Lumenis’s DMSt demonstrated a reduction in lid laxity by at least 75%, an improvement in blinking quality by at least 70%, and a significant 286% increase in tear break-up time (TBUT).”
Also: Check out what these dry eye experts have to say about it.
Sounds impressive … so where can I see this in action?
Are you attending Vision Expo East in Orlando, Florida, later this month (Feb. 19-22)?
If so, you’re in luck: Lumenis will debut OptiLIFT at its booth (#F1829)—stop by to check it out.
If not, click here for more information on the device, including how you can add it to your clinical practice.